Category: Cerapedics Inc.
Here's a look at some of the top funding stories for medical device companies this week.
Colorado-based Cerapedics closes $9 million in venture debt financing from GE Capital's Health Financial Services in support of the i-FACTOR Peptide Enhanced Bone Graft.
Tech and healthcare giant GE (NYSE:GE) put some skin in Cerapedics and its i-FACTOR bone graft, funding a $9 million venture debt financing round for the Colorado-based company.
Matthew Scott, former director of operations for Zimmer Holdings' dental business, is named senior vice president of operations for custom knee implant maker ConforMIS.
ConforMIS lured Zimmer's dental business operations director, Matthew Scott, away to be its new chief operating officer as it looks to scale up its customized knee implant business.
The Bedford, Mass.-based medical device company said Scott bring's a decade's worth of ops experience from his tenure at Zimmer. ConforMIS makes knee replacement implants and instrumentation that are custom-fit to patients' morphology.
Medical device company Cerapedics raises $19 million in a Series C funding round for its cervical spine bone graft technology.
Cerapedics said it closed a Series C equity round worth $19 million, led by new investors MedImmune Ventures and CVF LLC, an affiliate of Henry Crown & Co.
Existing backers OrbiMed Advisors and NGN Capital also participated, according to a press release.
The Dow Jones Industrial Average breaks 13,000 for the first time since the Lehman Brothers collapse triggered an economic implosion, before falling back to close just under that high-water mark; also, Teleflex inks PCA pump GPO deal; a Funding Roundup; and analysts' ups and downs.
The Dow Jones Industrial Average, a longtime bellwether for the U.S. economy, flirted yesterday with a high-water mark not seen since Lehman Brothers' collapse triggered an economic implosion more than 4 years ago.
The Dow reached 13,005.04 at one point yesterday, before subsiding to close at 12,965.69 yesterday. It's the first time the index has climbed that high since May 2008.
Investors were heartened by a deal struck in the European Union to resolve Greece's debt crisis and by positive earnings results from a pair of American stalwarts.
Covidien wraps up enrollment for a post-market study on the effectiveness of the SilverHawk peripheral arterial disease treatment system it acquired in its $2.6 billion buyout of ev3 last year.
Covidien plc (NYSE:COV) said it has enough patients to evaluate the effectiveness of an arterial plaque removal system it acquired in its buyout of ev3 Inc. last year.